AdAlta (ASX:1AD) and Carina Biotech join forces to develop next-generation CAR-T cancer therapeutics - Video

Carina Biotech and AdAlta are collaborating to develop precision engineered CAR-T cell therapies that provide new hope for patients. AdAlta and Carina Biotech experts; Dr Deborah Rathjen, Carina Biotech CEO & Managing Director, Dr Tim Oldham, AdAlta CEO & Managing Director, Professor Shaun McColl, Vice President Chemokine Platform Technology at Carina Biotech, and Michael Foley PhD, AdAlta Chief Scientific Officer details how CAR-T therapy is revolutionising cancer treatment and the key challenges this collaboration will address.

#AdAlta #Car-T #collaboration #Carina #technology #cancertreatment #cancer